Several HDAC inhibitors are already approved for treatment of other cancers, but early clinical data show that HDAC inhibitors against solid tumors are far less effective than against hematological diseases, likely due to the pharmacokinetic differences in these two different tumor contexts (97). This evidence concerns the gene HDAC9 and hematologic disorder.